PolyPeptide Group (PPGN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 1.3B
Fair value as of: Jun 24, 2026
Analysis
PolyPeptide Group (PPGN) currently trades at CHF 39.55, while our model-based Fair Value estimate is CHF 17.15 — implying the stock looks roughly 56.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PolyPeptide Group (PPGN) undervalued?
What is the fair value of PPGN?
What is the quality score of PPGN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.